As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles.---This podcast is supported by an educational grant from Johnson & Johnson and Varian.---SYNPOSISThey discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care.---TIMESTAMPS---RESOURCESAmerican Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdfNational Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937